Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.85 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.61 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552787 | 0.89 | SLC16A3 (0.74) | AKR1C3POLBPFKFB3MAPTMEN1 | |
| SCHEMBL28666883 | 0.89 | AKR1C3 (0.71) | AKR1C3MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL788215 | 0.88 | AKR1C3 (0.67) | AKR1C3POLBPFKFB3MAPTMEN1 | |
| SCHEMBL6079752 | 0.88 | AKR1C3 (0.70) | AKR1C3POLBPFKFB3MAPTMEN1 | |
| SCHEMBL2825009 | 0.88 | GPR27 (0.74) | AKR1C3POLBMAPTMEN1KMT2A | |
| SCHEMBL6078674 | 0.87 | AKR1C3 (0.69) | AKR1C3POLBPFKFB3MAPTMEN1 | |
| SCHEMBL788335 | 0.86 | TCF4 (0.66) | AKR1C3POLBPFKFB3MAPTMEN1 | |
| SCHEMBL7782154 | 0.86 | ALDH1A1 (0.77) | AKR1C3POLBMAPTMEN1KMT2A | |
| SCHEMBL7313388 | 0.85 | PLAU (0.77) | AKR1C3POLBMAPTMEN1KMT2A | |
| SCHEMBL894613 | 0.85 | POLB (0.82) | AKR1C3POLBPFKFB3MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436925-B1 | BETTER ABLE TO CROSS MEMBRANES; INHIBITORS OF CYSTEINE PROTEASES LIKE CALPAIN I AND II AND CATHEPSIN B AND L, CAN THUS BE USED TO CONTROL DISEASES ASSOCIATED WITH AN ELEVATED ACTIVITY OF CALPAIN ENZYMES OR CATHEPSIN ENZYMES | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| US-6251917-B1 | Benzamidoaldehydes and their use as cysteine protease inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-26 | — | — | US | disclosed |
| US-6103720-A | ENZYME INHIBITORS; ANTIICHEMIC AND -TUMOR AGENTS; STROKES; ALZEIMER'S DISEASE | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-15 | — | — | US | disclosed |
| CN-1245486-A | Ketobenzamides as calpain inhibitors | BASF AG (DE) | 2000-02-23 | — | — | CN | disclosed |
| CN-1238761-A | benzamide aldehydes and their use as cysteine protease inhibitors | BASF AG (DE) | 1999-12-15 | — | — | CN | disclosed |
| EP-0831800-A4 | ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS | DIMENSIONAL PHARM INC (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5741819-A | THROMBOSIS INHIBITORS; ANTIINFLAMMATORY AGENTS; NEURODEGENERATIVE DISORDERS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0831800-A1 | ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5612378-A | TREATING THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS OR INFLAMMATION | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-03-18 | — | — | US | disclosed |
| WO-1996040100-A1 | ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996039380-A1 | BIS-ARYLSULFONYLAMINOBENZAMIDE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |